MarketInOut Stock Screener Log In | Sign Up
 

Enliven Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Enliven Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,072.24 mln
Float60.95 mln
Earnings Date11/18/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

74.62
Transformational upside

Relative Strength

77 / 100
Strongly outperforming

Debt / Equity

0.00
Debt-free

ROE

-19.10
Negative

ROA

-18.61
Deeply negative

Business Description

Enliven Therapeutics is a drug development company working to create new treatments for cancer patients. Founded in 2019 and based in Boulder, Colorado, the company is currently running early-stage clinical trials for two experimental medicines ? one targeting a form of leukemia and another aimed at lung cancer and related tumor types. Both treatments are designed as precisely targeted drugs intended to block the specific biological signals that drive cancer growth.

Key Fundamentals

EPS-1.67
ROE-19.10
ROIC-1,507
ROA-18.61
EBITDA, mln-106
EV / EBITDA-20.03
EV / EBIT-20.01

Quote Details

Last 41.52
Change -0.41 (-0.98%)
Open 41.49
Volume 2,297,502
Turnover 95,392,288
Average Volume 1,402,786

Financial Ratios

Leverage Ratio1.02
Current Ratio64.07
Price / Book3.77
Price / Tangible Book3.77
Debt / Equity0.00

Financial Strength

Piotroski F-Score 3 / 9
Price to Intrinsic Value15.87
1-Year Target Price74.62
Short Ratio7.20
Short % of Float20.37

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 11.25% 95 / 100   
1 Month -8.08% 33 / 100   
2 Months -19.64% 23 / 100   
6 Months -6.17% 40 / 100   
1 Year 103% 97 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog